{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Faldaprevir%3A+24-week+treatment", "query": { "intervention": "Faldaprevir: 24-week treatment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T20:46:00.388Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01830127", "title": "BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "BI 207127 high dose", "type": "DRUG" }, { "name": "Faldaprevir", "type": "DRUG" }, { "name": "BI 207127 low dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 35, "start_date": "2013-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 6, "location_summary": "La Mesa, California • San Diego, California • DeLand, Florida + 3 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Arlington", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830127" }, { "nct_id": "NCT01330316", "title": "A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 119, "start_date": "2011-07", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 20, "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330316" }, { "nct_id": "NCT00984620", "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha (IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 160, "start_date": "2009-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 6, "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more", "locations": [ { "city": "Tulepo", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984620" }, { "nct_id": "NCT01399619", "title": "Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI201335", "type": "DRUG" }, { "name": "BI201335 24W", "type": "DRUG" }, { "name": "Bi 201335", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 310, "start_date": "2011-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399619" }, { "nct_id": "NCT01358864", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha (IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 678, "start_date": "2011-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 18, "location_summary": "North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358864" }, { "nct_id": "NCT00774397", "title": "Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335 NA 240 mg QD / LI", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI 201335 NA 120mg QD / LI", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg QD", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 719, "start_date": "2008-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774397" }, { "nct_id": "NCT01297270", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 658, "start_date": "2011-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297270" }, { "nct_id": "NCT01732796", "title": "IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BI 201335 (Faldaprevir)", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "Faldaprevir (BI 201335)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 470, "start_date": "2012-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 24, "location_summary": "Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732796" }, { "nct_id": "NCT01728324", "title": "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 207127-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 24-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 24-week treatment", "type": "DRUG" }, { "name": "Ribavirin-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 16-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 16-week treatment", "type": "DRUG" }, { "name": "RBV: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 16-week treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 496, "start_date": "2012-11", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 31, "location_summary": "North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01728324" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-10-03T20:46:00.388Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" } ] }